81,75 €
19,19 %heute
L&S, 27. Februar, 22:52 Uhr
ISIN
US53220K5048
Symbol
LGND
Berichte
Sektor
Industrie

Ligand Pharmaceuticals Incorporated Aktie News

Neutral
Seeking Alpha
etwa 6 Stunden alt
Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript
Neutral
Business Wire
etwa 10 Stunden alt
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “2023 was a transfor...
Neutral
Business Wire
5 Tage alt
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral admin...
Neutral
Business Wire
11 Tage alt
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments. Both executives will report to CEO Todd Davis. “Rich and Karen strengthen our commercial and clinical bench, better posi...
Neutral
Business Wire
14 Tage alt
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Tuesday, February 27, 2024, and will hold a conference call at 8:30 a.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference...
Neutral
Business Wire
16 Tage alt
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, today announced the publication of research in Nature Machine Intelligence showing that its NeuralPLexer technology outperforms other state-of-the art systems in predicting the structure of protein-ligand complexes as well as the conformationa...
Neutral
Business Wire
26 Tage alt
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that effective February 1, 2024, Ligand's Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 93,700 shares of its common stock, 32,750 restricted stock units (“RSUs”) and 40,000 performance stock units (“PSUs”) (at the target level) to two non-execut...
Positiv
Reuters
etwa 2 Monate alt
Ligand Pharmaceuticals' topical treatment for a viral skin infection has received approval from the U.S. health regulator, the company said on Friday, marking the first-ever at-home approved treatment for the condition in the country.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen